1007572-09-9

Basic information

• Product Name: 3-difluoromethyl-5-methoxy-benzonitrile
• Synonyms: 3-difluoromethyl-5-methoxy-benzonitrile
• CAS NO: 1007572-09-9
• Molecular Weight: 183.157
• Mol File: 1007572-09-9.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 3-difluoromethyl-5-methoxy-benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-difluoromethyl-5-methoxy-benzonitrile(1007572-09-9)
• EPA Substance Registry System: 3-difluoromethyl-5-methoxy-benzonitrile(1007572-09-9)

Safety Data

• Hazardous Substances Data: 1007572-09-9(Hazardous Substances Data)

Upstream product

• 21962-46-9 3-formyl-5-methoxy-benzonitrile 

Downstream Products

• 874974-85-3 3-(difluoromethyl)-5-hydroxybenzonitrile 

Relevant articles and documents

HETEROCYCLIC ANTIVIRAL COMPOUNDS

Compounds of formula I, wherein R1, R2, R3, X1, X2 and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

Non-nucleoside reverse transcriptase inhibitors

Compounds of formula I, wherein R1, R2, R3, R4, Ra, X, X1, and Y are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

Non-nucleoside reverse transcriptase inhibitors

The present invention provides compounds of formula I where R1 to R4 are as defined herein which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides for methods of treating or preventing HIV infection with compounds according to formula I and compositions containing the same. The invention still further provides process for the preparation of compounds of formula I wherein R4 is A1 and X1 is NH or O.